

none of which apply in this instance. Nonetheless, to address the substance of the rejection, the following amendments are presented.

A. Claim Amendments

Pending claims 1-21 have been canceled without prejudice and replaced with new claims 52 to 94.

New independent claim 52 is based upon pending claim 1 but incorporates the elements of claim 13 which is objected to only for depending upon a rejected independent claim. Consequently, this amendment distinguishes the claim over the cited references. The references cited discuss correlations between the enzyme β -glucocerebrosidase and certain forms of lysosomal storage disorders (LSDs). The cited references make no reference to the LSD markers listed in claim 52. For this reason, claim 52 is allowable. The claims that directly or indirectly depend upon claim 52 (claims 53 to 74) are also allowable for at least the same reason.

New independent claim 75 is directed at methods related to the preceding claims. These methods comprise assaying enzymes, polypeptides or proteins that are associated with the occurrence, development or onset of an LSD. The LSD being assayed is one in which the level of the LSD marker in the subject is elevated relative to the level of the LSD marker in a control. Claim 75 distinguishes over the cited references because the claim is directed towards markers whose level is increased, whereas the cited references describe how a deficiency in β -glucocerebrosidase is correlated with certain LSDs. Thus, claim 75 is patentable over the cited references. Claims directly or indirectly dependent upon claim 75 are patentable for at least the same reason.

The other independent claim (claim 93) is directed at other related methods that comprise assaying for LAMP-1, LAMP-2 or LIMP-II to detect an LSD in a patient pre-symptomatically. These particular markers are not discussed in the cited references. Hence, claim 93, and the claim dependent on it (claim 94), are patentable over the cited art.

B. Claim Support

1. Claims 53 to 74.

As noted *supra*, claim 52 is based on pending claim 1 and incorporates the elements of claim 13. Thus, claims 53-74 generally find support in original claims 13-15, as well as elsewhere throughout the specification (see, *e.g.*, the abstract; page 5, lines 5-8; and page 41, lines 9-13).

Claims 58-62 generally correspond to original claims 19-21, and find further support at page 9, at lines 1-22, for example.

Claims 63-64 correspond to original claims 16 and 17.

Claims 65-73 generally correspond to original claims 2-10.

2. Claims 75 to 92.

These claims find general support throughout the specification (see, *e.g.*, page 4, line 2 to page 5, line 3; and the examples).

Claims 78-81 are supported at page 4, line 29 to page 5, line 3, for example.

Claims 82-83 find support throughout the specification (see, *e.g.*, page 5, lines 3, 16 and 18; page 6, lines 6 and 21; and throughout the Examples, such as page 24, lines 5-12).

Claims 84-92 are supported at the points of the specification indicated *supra*.

3. Claims 93 and 94.

These claims find support within the specification as indicated above for the other claims and at Example 1, for instance.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Peter J. Meikle
Application No.: 09/180,657
Page 10

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at .



Respectfully submitted,

A handwritten signature in cursive script, reading 'Scott Ausenhus'.

Scott L. Ausenhus
Reg. No.: 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (303) 571-4000
Fax: (303) 571-4321
DE 7017135 v1